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Abstract
Background: Perinatal exposure to hyperhomocysteinemia might disturb neurogenesis during
brain development and growth. Also, high levels of homocysteine trigger neurodegeneration in
several experimental models. However, the putative mechanisms of homocysteine-induced toxicity
in the developing nervous system have poorly been elucidated. This study was aimed to investigate
homocysteine effects in undifferentiated neuroblastoma cells, Neuro2a.
Results: A 4 h exposure to homocysteine in a concentration range of 10–100 μM did not affect
cell viability and ROS production in Neuro2a cell cultures. Instead, ROS levels were increased by
two-three folds in cells treated with 250 μM and 500 μM homocysteine, respectively, in
comparison with control cells. Also, the highest homocysteine dose significantly reduced the viable
cell number by 40%. Notably, the treatment with homocysteine (250 μM–500 μM) in the presence
of antioxidants, such as N-acetylcysteine and IRFI 016, a synthetic α-tocopherol analogue,
recovered cell viability and significantly reduced homocysteine-evoked increases in ROS
production. Moreover, antioxidants, particularly IRFI 016, were able to counteract NF-κB
activation induced by 250 μM homocysteine.
Cell treatment with 250 μM homocysteine also triggered the onset of apoptosis, as demonstrated
by the increased expression of early apoptotic markers such as Bax, caspase-3 and p53. In contrast,
Bcl2 expression was not affected by homocysteine exposure. Interestingly, the specific inhibition of
NF-κB nuclear translocation by the synthetic peptide SN50 was able to almost completely suppress
the homocysteine-evoked rises in pro-apoptotic protein expression as well as in caspase-3 activity.
Further, also IRFI 016 and N-acetylcysteine were able to significantly reduce caspase-3 activation
induced by homocysteine treatment.
Conclusion: These observations suggest an involvement of redox state alterations and activated
NF-κB in apoptosis onset triggered by homocysteine in neuroblastoma cells Neuro2a. However,
further investigations are needed to characterize molecular events involved in the NF-κB activation
induced by homocysteine.
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Background
Homocysteine (Hcy) is a non-proteic sulfur-containing
amino acid product of methionine metabolism. Hyperho-
mocysteinemia is determined by genetic factors, such as
deficiency in enzyme activities involved in homocysteine
remethylation and transulphuration pathways, and/or
reduced dietary intake of folate, vitamin B6 and vitamin
B12 [1]. Increased plasma Hcy levels are a well known risk
factor for cardiovascular diseases, and have also been
associated with neurodegenerative disorders, such as
Alzheimer's disease and Parkinson's disease, and cogni-
tive dysfunction in the elderly [2-4]. Moreover, perinatal
exposure to hyperhomocysteinemia might disturb neuro-
genesis during brain development and growth, as well as
hereditary severe hyperhomocysteinemia leads to a vari-
ety of neurological impairments in children [5,6]. How-
ever, the putative mechanisms of homocysteine-induced
toxicity in the developing nervous system have poorly
been elucidated.
Hcy induces neurotoxicity in human and murine neuro-
nal cells through several mechanisms, including over-
stimulation of NMDA receptors, oxidative stress and DNA
damage [7-9]. Hcy is excitotoxic at least as glutamate and
also enhances glutamate excitotoxicity [9]. Moreover,
while normal activation of NMDA receptors can provoke
both excitation and inhibition, Hcy only elicited excita-
tion in cerebellar neurons [7].
Recently, a novel mechanism for Hcy neurotoxicity has
recently been described. This involves the inhibition of
cytochrome oxidase activity following copper binding by
Hcy [10]. Also, previous studies demonstrated that high
Hcy levels cause an imbalance in the redox status home-
ostasis with generation of toxic reactive oxygen species
(ROS) [11]. The excess of ROS production triggers cell
cycle arrest and apoptosis, finally leading to neurodegen-
eration [12].
A growing body of evidence suggests that ROS-induced
cell damage results from or is accompanied by inflamma-
tory processes. It has been shown that NF-κB activation
plays a pivotal role in the up-regulation of many inflam-
matory genes, whose products are putatively involved in
apoptosis [13]. However, the role of NF-κB in neuronal
death is controversial, and the effects of NF-κB nuclear
translocation in cell response still remain unclear. Indeed,
it has been reported that NF-κB activation in neurons is
protective against degeneration, whereas in microglia pro-
motes cell death [13].
The present study was designed to investigate the role of
pro-oxidant effects of Hcy exposure in undifferentiated
neuroblastoma cells, Neuro2a, and the possible involve-
ment of NF-κB pathway in Hcy-induced cell injury.
Methods
Materials
Eagle's Minimal Essential Medium (MEM), foetal bovine
serum (FBS) and antibiotics were from Invitrogen Life
Technologies (Milano, Italy). The caspase-3 substrate Ac-
Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-
Leu-Ala-Pro-Asp-Glu-Val-Asp-p-nitroaniline (DEVD-
pNa), D, L-Hcy, N-acetylcysteine (NAC), non-enzymatic
cell dissociation solution, and other chemicals of analyti-
cal grade were from Sigma (Milano, Italy). Rabbit polyclo-
nal antibody against Bax was from Chemicon (USA).
Mouse monoclonal antibodies against Bcl-2 and caspase-
3 were from BioVision (Mountain View, USA). Rabbit pol-
yclonal antibody against p53, mouse monoclonal anti-
bodies against β-actin as well as p50 (sc-8414X) and p65
(sc-8008X) NF-κB subunits, and the NF-κB inhibitor,
SN50, were from Santa Cruz Biotechnology (DBA,
Milano, Italy). The oligonucleotide probe containing the
NF-κB consensus sequence present in the κ-light chain
promoter was synthesised by MWG Biotech (Monza,
Italy). Kodak X-ray film was from Kodak (Milano, Italy).
IRFI 016, a synthetic α-tocopherol analogue, was gener-
ously supplied by Biomedica Foscama Research Centre
(Frosinone, Italy).
Cell culture and treatment
Mouse neuroblastoma cells Neuro2a (ATCC-CCL 131)
were grown in MEM, supplemented with 10% (vol/vol)
FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μg/ml
streptomycin and 50 U/ml penicillin, at 37°C in a 5%
CO2/95% air humidified atmosphere. Cell cultures were
maintained for at least two weeks, with medium renewal
every two days.
Subconfluent cells were treated with Hcy (10–500 μM) for
4 h in the presence or absence of antioxidant compounds,
such as NAC (500 μM) and IRFI 016 (80 μM), which were
added to the culture medium 30 min prior to Hcy treat-
ment. Four replicates were performed for each sample.
A subset of experiments was carried out using SN50 (50
μg/ml), a synthetic peptide able to specifically inhibit the
nuclear translocation of NF-κB, that was added to cell cul-
tures 30 min prior to Hcy exposure.
ROS production
In order to evaluate ROS production, Hcy-treated or
untreated Neuro2a cells, cultured in 12-well culture
plates, were incubated for 30 min with dichlorodihy-
drofluorescein diacetate (H2DCF-DA) (5 μM). Then, cells
were washed with phosphate-buffered saline (PBS),
detached with non-enzymatic cell dissociation solution,
and resuspended in 300 μl of PBS supplemented with 0.1
M KH2P04 and 0.5% Triton X-100. Supernatants were
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analyzed under fluorescein optics, as previously described
[14].
Cell viability assay
To assess Hcy effects on cell viability, an MTT (3-(4, 5-
methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide)
reduction assay was performed. After Hcy treatment,
Neuro2a cells, grown in 96-well culture plates, were incu-
bated with fresh medium containing MTT (0.5 mg/ml) at
37°C for 4 h. Then, insoluble formazan crystals were dis-
solved in 100 μl of a 10% (w/v) SDS solution in HCl 0.01
M. The optical density in each well was evaluated by spec-
trophotometrical measurement at 540 nm with a Sunrise
microplate reader (Tecan Italia, Cologno Monzese, Italy).
The percent cell viability was assessed by the absorbance
ratio of Hcy-treated vs untreated cells. All experiments
were made in triplicate.
Western blotting
After treatment, Neuro2a cells were homogenized on ice.
Proteins (30 μg) were separated by SDS-PAGE onto 8.5%
gel, and transferred to nitrocellulose membranes. Blots
were blocked overnight at 4°C with 5% non-fat dry milk;
then, membranes were incubated for 1 h at room temper-
ature, on a rotating device, with mouse monoclonal anti-
bodies against either Bcl-2, or caspase-3 or β-actin
(diluted 1:1000 in TBS-T) and rabbit polyclonal antibod-
ies against either Bax or p53 (diluited 1:2000 and 1:200,
respectively, in TBS-T), followed by incubation for 1 h
with horseradish peroxidase-conjugated anti-mouse IgG
(1:1500 for Bcl-2, and 1:2500 for caspase-3 and β-actin, in
TBS-T) or anti-rabbit IgG (1:2500 for Bax, and 1:1000 for
p53, in TBS-T). Blots were developed by ECL chemilumi-
nescence detection system kit using Kodak film. Bands
were scanned and quantified by densitometric analysis
with an AlphaImager 1200 System (Alpha Innotech, San
Leandro, CA, USA), after normalisation against β-actin.
Caspase-3 activity assay
After cell lysis, insoluble proteins were removed by cen-
trifugation at 1,000 × g for 3 min at 4°C. A 50 μl aliquot
of 2× reaction buffer/DTT mix, and 5 μl of 1 mM caspase-
3 substrate DEVD-pNa (final concentration 50 μM) were
added to the supernatants. Samples were incubated at
37°C for 60 min, and then DEVD-pNa cleavage was eval-
uated by measuring sample absorbance at 405 nm, using
DU 800 spectrophotometer (Beckman Coulter, Fullerton,
CA, USA). Measurements were calibrated against a stand-
ard linear regression curve of p-Na. Caspase activity was
defined as nmol pNA released per hour per mg of protein
(nmol/h/mg protein).
Electrophoretic mobility shift assay (EMSA)
The presence of NF-κB DNA binding activity in cell
nuclear extracts was evaluated by EMSA and supershift
assay, as described by Caccamo et al. [15].
Statistical analysis
All values are presented as means ± SEM. Statistical analy-
sis was performed using one-way ANOVA, followed by
Newman-Keuls post-hoc test.
Results
To evaluate Hcy-induced cell redox status alterations,
Neuro2a cell cultures were exposed to different Hcy doses
(10–500 μM), in the presence or absence of NAC (500
μM) and IRFI 016 (80 μM). Hcy did not significantly
affect ROS levels in Neuro2a cells when used in a concen-
tration range of 10–100 μM. Higher Hcy concentrations,
i.e. 250–500 μM, produced a two-three fold increase in
ROS production, respectively, in comparison to untreated
cells. The incubation of cell cultures with Hcy in the pres-
ence of either NAC or IRFI 016 was able to strongly coun-
teract Hcy effects on ROS production (Fig. 1A). Notably, a
higher protective effect was displayed by IRFI 016, reduc-
ing Hcy-evoked increases in ROS levels by 35%, compared
with a 20% reduction achieved in the presence of NAC
(Fig. 1A).
The MTT assay demonstrated that the treatment with 10–
250 μM Hcy did not significantly affect the number of via-
ble cells compared with controls, while 500 μM Hcy dras-
tically reduced cell viability to less than 40% (Fig. 1B).
Notably, IRFI 016 and NAC were able to recover cell via-
bility (Fig. 1B). The subsequent experiments were carried
out using 250 μM Hcy, in order to minimize alteration in
cell homeostasis dependent on massive cell necrosis.
The possible occurrence of NF-κB activation, concomi-
tantly with redox state alterations induced by Hcy, was
investigated by EMSA. We demonstrated an increase in
DNA binding activity by heterodimer NF-κB complexes,
mainly composed by p50 and p65 subunits, in nuclear
extracts of Hcy-treated neuroblastoma cells in comparison
with untreated ones, where lower amounts of active NF-
κB complexes were found (Fig. 2A–C). Moreover, as
expected, the incubation with SN50 significantly inhib-
ited NF-κB nuclear translocation (Fig. 2A–B). Notably,
when Neuro2a cells were incubated with Hcy (250 μM) in
the presence of IRFI 016 (80 μM), a significant reduction
of NF-κB levels was observed (Fig. 2A–B). These data sug-
gest a direct relationship between Hcy-induced oxidative
stress and NF-κB activation.
In order to better evaluate Hcy effects on cell damage in
Neuro2a cells, we examined the expression of known pro-
tein markers of apoptosis onset. The treatment with HcyBMC Neuroscience 2008, 9:62 http://www.biomedcentral.com/1471-2202/9/62
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(250 μM) for 4 h significantly increased Bax protein levels
in comparison with control cells, whereas Bcl-2 expres-
sion was not affected (Fig. 3). Interestingly, the incubation
with Hcy in the presence of SN50 reduced Hcy-induced
Bax up-regulation while did not affect Bcl-2 levels (Fig. 3).
The treatment of Neuro2a cells with Hcy also caused the
caspase-3 up-regulation (Fig. 4), that was accompanied by
a significant increase in caspase-3 activity compared with
control cells (Table 1).
Interestingly, in Hcy-exposed cells, the SN50-mediated
specific NF-κB inhibition lowered high levels of caspase-3
protein (Fig. 4) and enzyme activity (Table 1). The addi-
tion of either IRFI 016 (80 μM) or NAC (500 μM) was also
able to reduce Hcy-induced increases in caspase-3 activity
by 32% and 28% respectively (Table 1).
Effects of Hcy on ROS production (A) and cell viability (B) in  neuroblastoma Neuro2a cells Figure 1
Effects of Hcy on ROS production (A) and cell viabil-
ity (B) in neuroblastoma Neuro2a cells. ROS produc-
tion was measured by DCF formation as reported by Lee et 
al. [14]. Cell viability was evaluated by MTT assay as 
described in Materials and Methods. Results shown are mean 
± SEM of three-five separate experiments. *p < 0.05 and **p 
< 0.01 significant differences in comparison with untreated 
cells; §p < 0.05 and §§p < 0.01 significant differences in com-
parison with Hcy-treated cells.
Hcy treatment elicited NF-κB activation in Neuro2a cells Figure 2
Hcy treatment elicited NF-κB activation in Neuro2a 
cells. A) Detection by EMSA of NF-κB DNA binding 
activity in nuclear extracts of untreated or Hcy-
treated Neuro2a cells. After a 4 h incubation with 250 μM 
Hcy, in the presence or absence of either IRFI 016 (80 μM) 
or the NF-κB specific inhibitor SN50 (50 μg/ml), NF-κB acti-
vation was evaluated by incubation of nuclear proteins (6 μg) 
with a 40-mer biotinylated oligonucleotide probe containing 
the NF-κB consensus sequence. B) Densitometric analysis of 
NF-κB activated complexes. The amount of NF-κB activated 
complexes was significantly increased by Hcy treatment. 
Notably, IRFI 016 as well as SN50 strongly reduced Hcy-
increased NF-κB levels. Results shown were from three sep-
arate experiments. *p < 0.05 significant differences in com-
parison with untreated cells, and §§p < 0.01 significant 
differences in comparison with Hcy-treated cells. C) Super-
shift analysis of NF-κB activated complexes. A supershift 
assay, carried out by incubating nuclear proteins with specific 
monoclonal antibodies against p50 and p65 NF-κB subunits, 
demonstrated that NF-κB activated complexes were p50/p65 
heterodimers.BMC Neuroscience 2008, 9:62 http://www.biomedcentral.com/1471-2202/9/62
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To further evaluate the NF-κB involvement in Hcy-evoked
apoptosis in Neuro2a cells, Hcy effects on the expression
of p53 were assessed in the presence or absence of SN50.
Indeed, Hcy treatment induced p53 up-regulation, that
was strongly reduced in the presence of SN50 (Fig. 5).
Discussion
In this study, we demonstrated that exposure to micromo-
lar Hcy concentrations triggered redox state alterations in
Neuro2a cell cultures. One cannot exclude that the use
here of D, L-homocysteine might have led to somewhat
unphysiological results. However, D, L-homocysteine has
been widely used in several experimental models, and the
results observed are superimposable with physiological
responses. Indeed, our observations agree with previous
results showing a ROS-mediated alterations following
Effects of Hcy treatment on Bcl-2 and Bax expression in  Neuro2a cells Figure 3
Effects of Hcy treatment on Bcl-2 and Bax expression 
in Neuro2a cells. Neuro2a cells were treated with 250 μm 
Hcy for 4 h in the presence or absence of SN50, the specific 
NF-κB inhibitor, that was added to cell cultures 20 min prior 
to incubation with Hcy. The immunoblots, with relative den-
sitometric analysis after normalization against β-actin, show 
Hcy-evoked effects on the expression of anti-apoptotic and 
pro-apoptotic markers, such as Bcl-2 and Bax, respectively. 
Results are expressed as mean ± SEM of five independent 
experiments. *p < 0.05 compared with control cells, §p < 
0.05 in comparison with Hcy-treated cells.
Table 1: Caspase-3 activity in Neuro2a cells exposed to Hcy.
pNa amounts (nmol/h/mg prot)
Control 60 ± 3.3
+ Hcy (250 μM) 142 ± 15.1 **
+ Hcy (250 μM) + SN50 (30 μg/ml) 87 ± 9.5 *
+ Hcy (250 μM) + IRFI 016 (80 μM) 96 ± 7.9 *
+ Hcy (250 μM) + NAC (500 μM) 102 ± 9.2 *
SN50 (30 μg/ml) 53 ± 2.9
IRFI 016 (80 μM) 42 ± 3.4
The evaluation of caspase-3 activity was carried out based on measurements of specific cleavage of DEVD-pNa as described in Materials and 
methods. Results are mean ± SEM of six experiments. * p < 0.05 and **p < 0.01 significant differences in comparison to control cells.
Western blot analysis of caspase-3 expression in Hcy-treated  and untreated Neuro2a cells Figure 4
Western blot analysis of caspase-3 expression in Hcy-
treated and untreated Neuro2a cells. After a 4 h Hcy 
treatment, in the presence or absence of the specific NF-κB 
inhibitor SN50, cell proteins were probed with monoclonal 
antibodies against caspase-3 and β-actin (figure top). A densit-
ometric analysis of immunoblots (figure bottom) was also car-
ried out after normalization against β-actin. Results were 
similar in three separate experiments. *p < 0.05 significant 
difference in comparison with untreated cells; §p < 0.05 in 
comparison to Hcy-treated cells.BMC Neuroscience 2008, 9:62 http://www.biomedcentral.com/1471-2202/9/62
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Hcy exposure [16]. Although the precise mechanisms by
which Hcy increases oxidative stress are not yet com-
pletely understood, the prevention of Hcy-induced toxic-
ity by catalase suggests that hydrogen peroxide plays a role
as a mediator of oxidative injury leading to apoptosis [17-
19]. Indeed, folic acid supplementation has a protective
effect on Hcy-induced oxidative stress by reducing intrac-
ellular superoxide levels and, to a lesser extent, quenching
hydrogen peroxide [20]. Moreover, Hcy, inhibiting the
expression of antioxidant enzymes as well as the synthesis
of radical scavengers (e.g. glutathione peroxidase, super-
oxide dismutase), might potentiate the toxic effects of
ROS [21]. Also, Hcy decreases the tissue levels of vitamins
A, C and E, thereby reducing the antioxidant reserves [22].
On the other hand, antioxidant treatment with NAC and
vitamin E can prevent oxyradical generation in neuroblas-
toma cells related to increased Hcy or reduced folic acid
[22]. Based on these evidence, we chose to test Hcy effects
in the presence of the antioxidant IRFI 016, a synthetic
vitamin E analogue, that has previously been demon-
strated to be protective against oxidative stress induced by
excitotoxic amino acid [23]. Interestingly, IRFI 016 was
more effective than NAC, the precursor of intracellular
glutathione, in reducing Hcy-increased ROS levels. Fur-
ther, IRFI 016 was able to reduce NF-κB nuclear transloca-
tion. These effects suggest a cross-talk between oxidative
stress and inflammatory cascade in the alterations trig-
gered by Hcy in Neuro2a cells.
In human hepatoma cells, it has been reported that folate
deficiency-induced apoptosis is proceeded via the
enhanced activation of NF-κB, which results from the
Hcy-mediated overproduction of hydrogen peroxide [24].
In this study, we also demonstrated that the oxidative
stress induced by Hcy in Neuro2a cells involves the activa-
tion of NF-κB, which is inhibited by the antioxidant IRFI
016. Indeed, NF-κB is a redox-sensitive transcription fac-
tor which is crucial in the control of ROS-mediated apop-
tosis. Previous reports have shown that NF-κB activation
is a part of recovery processes after acute oxidative stress
induced by various stimuli, other than excitoxicity, in
astroglial cells [15,25-29]. Interestingly, depending on the
conditions and the cell type considered, NF-κB activation
has been shown to have opposite effects on the brain cell
survival. In fact, it has been shown that NF-κB inhibition
leads to loss of neuroprotection as well as activated NF-κB
induces the expression of anti-apoptotic Bcl-2 gene
[30,31]. On the contrary, the activation of NF-κB and
increase in the mRNA levels of pro-apoptotic Bax have
also been demonstrated in different stress conditions
including amyloid beta (Aβ)-induced oxidative stress in
microglial cells [32].
Among the κB-responsive genes possibly involved in the
control of neuronal cell death, various pro-apoptotic
genes are activated upon oxidative stress, and might medi-
ate NF-κB/Rel-induced cell death. Here, we observed that
the Hcy-induced NF-κB activation mediated the increase
in early protein markers of apoptosis onset, such as Bax,
caspase-3 and p53.
The cysteine proteases, caspases, are considered to play a
central role in the apoptotic processes, and trigger the
apoptotic cascade of proteolytic cleavage events in mam-
malian cells [33]. The most widely studied member of the
caspase family, caspase-3, is one of the key apoptosis exe-
cutioners that is responsible for the partial or total prote-
olytic cleavage of many proteins. In addition, the p53
protein plays an important role in genotoxic stress,
growth arrest, and cell death. Translocated NF-κB may
affect p53 phosphorylation, and subsequently, the
decrease of NF-κB activation lead to reduced p53 activity,
which had been confirmed on neurons exposure to DNA
damage [35].
Conclusion
NF-κB activation seems to be a critical event in the onset
of Hcy-induced apoptosis in neuroblastoma cells
Western blot analysis of p53 expression in Hcy-treated and  untreated Neuro2a cells Figure 5
Western blot analysis of p53 expression in Hcy-
treated and untreated Neuro2a cells. After a 4 h Hcy 
treatment, in the presence or absence of SN50, the specific 
NF-κB inhibitor, cell proteins were probed with monoclonal 
antibodies against p53 and β-actin (figure top). A densitomet-
ric analysis of immunoblots (figure bottom) was also carried 
out after normalization against β-actin. Results were similar 
in three separate experiments. *p < 0.05 significant difference 
in comparison with untreated cells.BMC Neuroscience 2008, 9:62 http://www.biomedcentral.com/1471-2202/9/62
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Neuro2a, given the significant decrease of apoptotic
marker expression observed in the presence of SN50-
mediated specific NF-κB inhibition. Interestingly, the pro-
tective effect displayed by the antioxidants IRFI 016 and
NAC, reducing caspase-3 activity, underscore a major role
for oxidative stress in Hcy toxic effects.
However, the increase in NF-κB DNA binding activity in
apoptotic cells did not address cause-effect relationships.
Considering the dual role of NF-κB in cells survival further
investigations are needed to elucidate its function in Hcy-
induced neuronal cell death.
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